2022
Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes
Deshpande S, Weinzimer SA, Gibbons K, Nally LM, Weyman K, Carria L, Zgorski M, Laffel LM, Doyle FJ, Dassau E. Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2022, 18: 363-371. PMID: 35971681, PMCID: PMC10973844, DOI: 10.1177/19322968221116384.Peer-Reviewed Original ResearchType 1 diabetesUnannounced exercisePercent timeGlucose standard deviationParents/guardiansSecondary outcomesAdverse eventsPrimary outcomeBlood glucose dataPump therapyPreliminary safetyAutomated Insulin DeliveryContinuous glucose monitoring dataPediatric participantsGlucose monitoring dataAge-based cohortsArtificial pancreas systemsLarge mealsInsulin deliveryGlucose dataYoung childrenDiabetesYounger cohortsChildrenCohortCambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial
Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium D, Hovorka R, Acerini C, Thankamony A, Allen J, Boughton C, Dovc K, Dunger D, Ware J, Musolino G, Tauschmann M, Wilinska M, Hayes J, Hartnell S, Slegtenhorst S, Ruan Y, Haydock M, Mangat J, Denvir L, Kanthagnany S, Law J, Randell T, Sachdev P, Saxton M, Coupe A, Stafford S, Ball A, Keeton R, Cresswell R, Crate L, Cripps H, Fazackerley H, Looby L, Navarra H, Saddington C, Smith V, Verhoeven V, Bratt S, Khan N, Moyes L, Sandhu K, West C, Wadwa R, Alonso G, Forlenza G, Slover R, Towers L, Berget C, Coakley A, Escobar E, Jost E, Lange S, Messer L, Thivener K, Campbell F, Yong J, Metcalfe E, Allen M, Ambler S, Waheed S, Exall J, Tulip J, Buckingham B, Ekhlaspour L, Maahs D, Norlander L, Jacobson T, Twon M, Weir C, Leverenz B, Keller J, Davis N, Kumaran A, Trevelyan N, Dewar H, Price G, Crouch G, Ensom R, Haskell L, Lueddeke L, Mauras N, Benson M, Bird K, Englert K, Permuy J, Ponthieux K, Marrero-Hernandez J, DiMeglio L, Ismail H, Jolivette H, Sanchez J, Woerner S, Kirchner M, Mullen M, Tebbe M, Besser R, Basu S, London R, Makaya T, Ryan F, Megson C, Bowen-Morris J, Haest J, Law R, Stamford I, Ghatak A, Deakin M, Phelan K, Thornborough K, Shakeshaft J, Weinzimer S, Cengiz E, Sherr J, Van Name M, Weyman K, Carria L, Steffen A, Zgorski M, Sibayan J, Beck R, Borgman S, Davis J, Rusnak J, Hellman A, Cheng P, Kanapka L, Kollman C, McCarthy C, Chalasani S, Hood K, Hanes S, Viana J, Lanning M, Fox D, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health 2022, 4: e245-e255. PMID: 35272971, DOI: 10.1016/s2589-7500(22)00020-6.Peer-Reviewed Original ResearchConceptsClosed-loop groupInsulin pump therapyType 1 diabetesControl groupBaseline HbAUsual carePump therapyClosed-loop insulin deliverySuboptimal glucose controlPediatric diabetes centersKey inclusion criteriaClosed-loop insulin delivery systemPrimary endpointBlock randomisationDiabetes CenterGlucose controlInsulin delivery systemsInclusion criteriaPrimary analysisTherapyInsulin deliveryMonthsG pumpHbADiabetes
2021
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.
Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherñavvsky D, Beck RW. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care 2021, 44: 473-478. PMID: 33355258, PMCID: PMC7818334, DOI: 10.2337/dc20-1729.Peer-Reviewed Original ResearchConceptsType 1 diabetesChildren 6Sensor-augmented pump therapyWeeks of useDiabetic ketoacidosisDays of useGlycemic controlSAP groupSevere hypoglycemiaPump therapyClinical trialsPercentage of timeCLC groupMean TIRDiabetesFurther evaluationCohortRCTsDlWeeksChildrenDaysExtended useParticipantsKetoacidosis
2020
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin dose adjustmentPhysician armDose adjustmentAcademic diabetes centerInsulin pump settingsPrimary efficacy measureSevere adverse eventsTarget glucose rangeInsulin pump therapyNon-inferiority trialArtificial intelligence-based decision support systemAdverse eventsInsulin titrationDiabetes CenterEfficacy measuresPump therapyPercentage of timePercentage of readingsGlucose levelsSix monthsContinuous glucose monitoring devicesDiabetesInsulin pumpGlucose monitoring devices
2018
Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.Peer-Reviewed Original ResearchConceptsType 1 diabetesSAP armPredictive low glucose suspendSensor-augmented pump therapyNew insulin delivery systemsRandomized Crossover StudySevere hypoglycemic eventsGlucose concentrationMin/dayMean glucose concentrationLow glucose suspendBasal-IQRebound hyperglycemiaSlim X2Glycemic controlPrimary outcomeCrossover studyMedian timeCrossover trialHypoglycemic eventsPump therapyInsulin delivery systemsPercentage of timeHypoglycemiaDiabetes
2016
Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance
Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdolescentAdolescent BehaviorAdultAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringCalibrationCohort StudiesDiabetes Mellitus, Type 1Drug Dosage CalculationsDrug MonitoringGlucoseHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinPancreas, ArtificialPrecision MedicineSubcutaneous TissueYoung AdultConceptsType 1 diabetesAdolescent cohortAdult cohortHybrid closed-loop systemPump therapyPercentage of timeGlucose valuesSensor-augmented pump therapyOverall glucose controlInsulin pump therapyOverall mean percentageDose insulinGlucose controlPreliminary safetyInsulin delivery systemsInitial cohortHybrid closed-loop controlClinical practiceSecond cohortCohortMean percentageTarget rangeOverall percentageDiabetesAdults
2013
The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*
Buckingham B, Beck R, Ruedy K, Cheng P, Kollman C, Weinzimer S, DiMeglio L, Bremer A, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*. Diabetes Technology & Therapeutics 2013, 15: 401-408. PMID: 23570538, PMCID: PMC3643224, DOI: 10.1089/dia.2013.0002.Peer-Reviewed Original ResearchConceptsType 1 diabetesMean glucose concentrationHybrid closed-loop controlMedian percentageHybrid closed-loop therapyType 1Sensor-augmented pump therapyPositive pancreatic autoantibodiesTrialNet Study GroupDays of diagnosisNormal glycemic controlΒ-cell functionGlucose concentrationClosed-loop therapyPancreatic autoantibodiesGlycemic controlSAP therapyPump therapyStudy groupGlucose levelsGlucose toxicityDay 2Day 3Glucose valuesTherapy
2006
Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin
Tsalikian E, Kollman C, Tamborlane W, Beck R, Fiallo-Scharer R, Fox L, Janz K, Ruedy K, Wilson D, Xing D, Weinzimer S. Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin. Diabetes Care 2006, 29: 2200-2204. PMID: 17003293, PMCID: PMC1584283, DOI: 10.2337/dc06-0495.Peer-Reviewed Original ResearchConceptsType 1 diabetesBasal insulinExercise sessionsFrequency of hypoglycemiaPrevention of hypoglycemiaRisk of hyperglycemiaInsulin pump therapyTarget heart rateCompletion of exerciseBlood ketone levelsStructured exercise sessionsYears of agePump therapyStudy groupKetone levelsHeart rateHypoglycemiaDay 1Crossover designDay 2DiabetesInsulinChildren 8Diabetes researchObservation period
2004
Rediscovery of insulin pump treatment of childhood type 1 diabetes.
Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95: 85-92. PMID: 15272243.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionInsulin pump therapyQuality of lifeSevere hypoglycemiaPump therapyLong-term microvascular complicationsEfficacy of CSIIType 1 diabetes mellitusWeight gainChildhood type 1 diabetesExcessive weight gainBasal infusion rateSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenContinuous glucose monitoringMicrovascular complicationsDiabetes mellitusPediatric patientsHemoglobin levelsNocturnal hypoglycemiaTreatment optionsNormal glycemiaInsulin infusion